1. Immunomodulation profile of the biosimilar trastuzumab MYL-1401O in a bioequivalence phase I study.
- Author
-
Audran, R., Chtioui, H., Thierry, A. C., Mayor, C. E., Vallotton, L., Dao, K., Rothuizen, L. E., Maghraoui, A., Pennella, E. J., Brunner-Ferber, F., Buclin, T., and Spertini, F.
- Subjects
IMMUNOREGULATION ,TRASTUZUMAB ,CYTOKINES ,GRANULOCYTE-macrophage colony-stimulating factor ,ANTIGENS - Abstract
The initial Phase-I single centre, single dose, randomized, double-blind, cross-over study was planned to assess the pharmacokinetic and pharmacodynamic bioequivalence of the trastuzumab biosimilar (MYL-1401O) compared to the reference Herceptin
® . Their respective immunomodulation profile presented in this paper involved healthy males receiving a single infusion of both monoclonals, separated by a washout period. Sixty parameters were assessed in total, including serum cytokines, peripheral mononuclear cell (PBMC) subsets, cell activation and response to recall antigens and mitogen, pre- and post- infusion, as well as a cytokine release assay (CRA) at baseline. Trastuzumab infusion induced a transient and weak peak of serum IL-6 at 6 h, and a modulation of mononuclear cell subset profile and activation level, notably CD16 + cells. Except for CD8 + T cells, there were no significant differences between Herceptin® and MYL-1401O. In CRA, PBMC stimulated with MYL-1401O or Herceptin® similarly secreted IL-6, TNF-α, IL-1β, GM-CSF, IFN-γ, and IL-10, but no or low level of IL-2. Interestingly, some observed adverse events correlated with IL-2 and IFN-γ in CRA. MYL-1401O exhibited a very similar immunomodulation profile to Herceptin® , strongly supporting its bioequivalence. This approach may thus be included in a proof-of-concept study. CRA may be used as a predictive assay for the evaluation of clinical monoclonals. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF